Immediate seizure controlling and drug selection is very important to yield optimal treatment effects and to prevent side effects due to long-term therapy. Phenytoin, carbamazapine and valproic acid are the first line drugs of anti-epilepsy that are commonly used worldwide for general tonic-clonic and parsial epilepsy. However, there are still many controversies to choose the best drug among them when the child is diagnosed as epilepsy for the first time. [9] [10] [11] [12] [13] Based on that, this study aimed to find the different effects of monotherapy of phenytoin, carbamazapine, and valproic acid on pediatric general tonic clonic and partial epilepsy.
Methods
We conducted a historical cohort study ( Figure 1 ). The primary outcome was the time of 12-month remission from seizures and the secondary outcomes were the withdrawal from treatment, time to last seizure after treatment, side effects and cure rate. We recruited one month until 18-year old children diagnosed as general tonic clonic or parsial epilepsy (based on clinical sign and EEG examination) treated with phenytoin, carbamazapine, or valproic acid routinely for more than two years in Sardjito Hospital from January 2000 to May 2007. This study was done from June 2007 to August 2007 in Sardjito Hospital Yogyakarta. Time to 12-month remission, was defined as time needed to achieve 12 month free of seizure since the first treatment up to the 36 months of follow up. We defined treatment withdrawal as the discontinuity of the treatment because of side effects or uncontrolled seizure. Time to remission was the time needed to achieve the last seizure during treatment. Cured was the condition free from seizure without treatment after two years free from seizure with treatment. The inclusion criteria were children with general tonic clonic or parsial seizure, including secondary generalized seizure who routinely visited the pediatric neurology. Age was between 1 month and 18 years. The patients were treated with phenytoin, carbamazapine or valproic acid for two years or more. We excluded non convulsive epilepsy, children with severe neurological disorder (i.e. cerebral palsy, microcephaly and hydrocephalus), brain tumors, and severe epileptic syndrome (i.e. West syndrome, Lennox-Gestaut syndrome and Landau-Kleffner syndrome). We divided the research into three groups of treatment: phenytoin group, carbamazapine group and valproic acid group.
Our assumption was by follow up for about three years, 80% of patients with phenytoin, 67% patients with carbamazapine and 78% patients with valproic acid achieved 12-month experienced remission. 14 The power of the trial would exceed 80% (by the log-rank statistic at P=0.05, two-tailed) to detect improvements to 20% seizure free. We chose the higher samples among the three therapy above, so we found that the sample size of this study was 41 patients for each group Chi-squared (X 2 ), t-test, ANOVA and survival analysis of Kaplan-Meier with log rank statistic were used to analyze the data. 15 
Results
Based on 399 medical records of epilepsy diagnosis during January 2000 up to May 2005, 273 medical records had diagnosis of general tonic clonic and parsial epilepsy, 175 had completed data that matched with the inclusion criteria, whereas 21 were excluded. Therefore, we had 154 medical records included in this study, that were 65 phenytoin group, 47 carbamazapine group and 42 valproic acid group. We collected all the data from 154 medical records, as the samples of this study.
Baseline characteristic data are shown in Table  1 . The mean time of 12 month remissions were similar among groups, but if we compared one by one, there was significant difference between carbamazapine and valproic acid (P=0.031, 95%CI 0.28;5.66) ( Table 2) . Overall, 69.5% patients achieved 12-month remission in the 36 month of follow up and it was not different among groups ( Table 2 ). Survival analysis showed that there were significant differences between phenytoin and valproic acid (P=0.007), carbamazapine and valproic acid (P=0.042), which was not found in phenytoin and carbamazapine (P=0.808) (Figure 2) . From sub-analysis based on diagnosis, we found only phenytoin and valproic acid that have significant difference (P=0.016) in the general tonic clonic epilepsy. We found no difference among groups of partial epilepsy, although in week 28 th all the patients in valproic acid group achieved 12-month remission.
There were adverse effects in the phenytoin and the carbamazapine groups (6.1% and 8.6%, Table  4 . Generally, all three drugs had good effect of treatment. Overall, 45.78% patients were cured and no significant difference among groups (P=0.40).
We calculated the relative risks with 95% confidence interval to compare the effect of treatment among the three drugs and phenytoin to be the control group. We found that valproic acid increased the possibility to achieve 12-month remission significantly when compared to phenytoin. The other variables were similar among groups ( Table 5) .
Discussion
There are several reviews represented the efficacy and tolerability of several antiepileptic drug, 9,16,17 but most of the studies were conducted in adults and only few studies in children. De Silva et al 14 and Verity et al 18 studies are two of few studies on childhood epilepsy investigated the efficacy of antiepileptic drug. They found that phenytoin, carbamazapine and valproate have similar efficacy and excellent controlling seizures. Our study showed different results. We found that valproic acid is better than phenytoin and carbamazapine to achieve 12 months remission. We analyzed the data by relative risk and survival analysis and revealed that valproic acid was better than phenytoin and carbamazapine significantly. Although the number of side effects is small, valproic acid had fewer side effects than phenytoin and carbamazapine. Other secondary outcomes were similar among phenytoin, carbamazapine and valproic acid.
The baseline characteristics data were similar. Genetic factor that contributes approximately 40% of etiology of childhood epilepsy 3 was only 9% in this study. However, the investigation was only from the family epilepsy history. Camfield 19 described that onset of epilepsy is less than 12 years old and the number of seizure less than 21 times before treatment is the best 
predictor to achieve remission. In this study, the two factors were similar. Each group had the same opportunity to get remission. The parental education and occupation were similar too. Therefore, they had the same chance to get medicines. There are limitations in this study. This study was a historical cohort. Recall bias becomes a main problem in this study. Although we had a complete data from medical records, we were not able to control compliance of taking the medicine every day. We concluded that the patients have good compliance if they come for routinely check up to the pediatric neurology clinic. The diagnostic criteria that was based on clinical appearance and EEG results, sometime were not sufficient to create definitive diagnosis. Misdiagnosis is still possible with the consequence of wrong treatment. The doses of the drugs are within the range of therapeutic dose, but we do not have certain protocol yet when to increase the dose. It will influence the time to get the remission because of the lateness in increasing the dose.
In conclusion, valproic acid increases the possibility of 12-month remission compared to carbamazapine or phenytoin as monotherapy in pediatric general tonic clonic and partial epilepsy without increasing side effects. The therapy effect of carbamazapine is not different significantly from that of phenytoin.
